
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Don’t miss our latest news! Sign up today for our free newsletter.
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Three nucleoside reverse transcriptase inhibitors (Zerit, Videx, and Retrovir) are 'significantly associated' with new-onset diabetes in HIV patients, according to study results released in Glasgow, Scotland, at the Eighth International Congress on Drug Therapy in HIV Infection. In addition, use of the nonnucleoside analog Viramune indicated that it helped protect against the onset of diabetes. In a surprise to the researchers, protease inhibitors did not show any relation to the development of diabetes despite their regular association with metabolic abnormalities in HIVers who use them. The research came from the 33,389-patient Data Collection on Adverse Effects of Antiretroviral Drugs Study, the largest cohort study'based across the United States, Europe, and Australia'following a group of patients taking anti-HIV drugs and charting the risk of certain side effects.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Don’t miss our latest news! Sign up today for our free newsletter.
Plus: Featured Video
Latest Stories
‘Kokomo City’ Gives a Searing Look Into Lives of Black Trans Sex Workers
August 18 2023 12:40 PM